Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

SA Transcripts 161.74K Followers Follow Madrigal Pharmaceuticals, Inc. ( MDGL ) Canaccord Genuity's 46th Annual Growth Conference August 11, 2026 12:00 PM EDT Company Participants Mardi Dier - Executive VP & CFO Carole Huntsman - Executive VP & Chief Commercial Officer David Soergel - Executive VP & Chief Medical Officer Conference Call Participants Edward Nash - Canaccord Genuity Corp., Research Division Presentation Edward Nash Canaccord Genuity Corp., Research Division Hi. Good afternoon, everyone. My name is Edward Nash, Senior Biotech Analyst here at Canaccord Genuity. It is my pleasure to have with us today the management team from Madrigal Pharmaceuticals. Joining us from the company, we have Mardi Dier, the Chief Financial Officer; Carole Huntsman, Chief Commercial Officer; and we also have David Soergel, who is the Chief Medical Officer. Thank you all for joining us today. Question-and-Answer Session Edward Nash Canaccord Genuity Corp., Research Division So from at least in the biotech world, we usually -- I would say Madrigal doesn't need any introductions because they were the company that got the first drug approved for a very large indication out there known as MASH. You've had a really impressive second quarter and with continued strong growth. Although the company does not provide specific revenue guidance, could you maybe talk to us a little bit about the commercial growth of Rezdiffra since its launch in April of '24? And how Madrigal positions Rezdiffra from a perspective of the long-term expectations? Mardi Dier Executive VP & CFO Yes. Great. Thanks, Ed, and thanks for having us. We really appreciate being here. Yes, we'll take -- I'll take a stab at answering that question. So at Madrigal, we've had excellent commercial growth since our launch in the first quarter of 2024, and we're focused very much on our 2 top priorities, which is building value for Rezdiffra, getting Rezdiffra to as many patients as we can and building our pipeline so we can